From chemistry to targeted cancer therapy: potent benzimidazole-1,2,3-triazole hybrid-loaded nanogels against breast and colorectal malignancies

Azizah M. Malebari, Mohamed A. M. Ali, Arafa Musa, Magdi E. A. Zaki, Sobhi M. Gomha, Moataz A. Soliman, Mohamed A. Abdelgawad, Della Grace Thomas Parambi, Mohamed R. Aouad, Hamada S. Abulkhair and Hany E. A. Ahmed

RSC Adv., 2025, 15, 47601
DOI: 10.1039/D5RA07972A

Synthesis and evaluation of photophysical, electrochemical, and ROS generation properties of new chalcogen-naphthoquinones-1,2,3-triazole hybrids

Luana S. Gomes, Érica O. Costa, Thuany G. Duarte, Mateus H. Köhler, Bruna M. Rodrigues, Vitor F. Ferreira, Fernando de C. da Silva, Bernardo A. Iglesias and Vanessa Nascimento

RSC Adv., 2023, 13, 34852
DOI: 10.1039/D3RA06977J

Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives

Hamada S. Abulkhair

RSC Adv., 2026, 16, 3034
DOI: 10.1039/D5RA08746E

Design, synthesis, molecular modeling, and antiproliferative evaluation of new 2-oxoindolin-3-ylidene thiazole derivatives

Aalaa F. El-Mokadem, Mohammed K. Abd El-Gaber, Pak Hei Chung, Siang-Boon Koh, Hoda Y. Hassan and Adel F. Youssef

RSC Med. Chem., 2025, 16, 3645
DOI: 10.1039/D5MD00332F

In vitroand computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-MProinhibitors

Ateyatallah Aljuhani, Hany E. A. Ahmed, Saleh K. Ihmaid, Abdelsattar M. Omar, Sultan S. Althagfan, Yaser M. Alahmadi, Iqrar Ahmad, Harun Patel, Sahar Ahmed, Mohannad A. Almikhlafi, Ahmed M. El-Agrody, Mohamed F. Zayed, Safaa Abdulrahman Turkistani, Shorouk H. Abulkhair, Mohammed Almaghrabi, Samir A. Salama, Ahmed A. Al-Karmalawy and Hamada S. Abulkhair

RSC Adv., 2022, 12, 26895
DOI: 10.1039/D2RA04015H

Novel isatin–triazole based thiosemicarbazones as potential anticancer agents: synthesis, DFT and molecular docking studies

Alia Mushtaq, Rabbia Asif, Waqar Ahmed Humayun and Muhammad Moazzam Naseer

RSC Adv., 2024, 14, 14051
DOI: 10.1039/D4RA01937G

Novel Benzochromenes: Design, Synthesis, Cytotoxicity, Molecular Docking and Mechanistic Investigations

Fatma G Abdulrahman, Hamada S Abulkhair, Riham A Zidan, Asmaa I Alwakeel, Ahmed A Al-Karmalawy and Ebtehal M Husseiny

Future Med. Chem., 2024, 16, 105
DOI: 10.4155/fmc-2023-0198

Structure-based development of 3,5-dihydroxybenzoyl-hydrazineylidene as tyrosinase inhibitor; in vitro and in silico study

Azzam Bagheri, Shahram Moradi, Aida Iraji and Mohammad Mahdavi

Sci Rep, 2024, 14
DOI: 10.1038/s41598-024-52022-6

New benzothiazole-indole-1,2,3-triazole-N-phenylacetamide derivatives as cytotoxic agents: Design, synthesis, and in vitro cytotoxic evaluations

Amir Mohammad Taherkhani, Mohammad Hosein Sayahi, Bahareh Hassani, Navid Dastyafteh, Maryam Mohammadi-Khanaposhtani, Elahe Rafiei, Maryam Meshkani, Sajedeh Safapoor, Mohammadreza Mohajeri Tehrani, Bagher Larijani, Mohammad Mahdavi and Omidreza Firuzi

Journal of Molecular Structure, 2025, 1336, 142089
DOI: 10.1016/j.molstruc.2025.142089

An alternative technique for cyclization synthesis, in vitro anti-esophageal cancer evaluation, and molecular docking of novel thiazolidin-4-one derivatives

Ahmed Majeed Jassem, Adil Muala Dhumad, Jinan Khudhair Salim and Hadi Abdalsamad Jabir

Journal of Molecular Structure, 2023, 1280, 135079
DOI: 10.1016/j.molstruc.2023.135079

The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia

Esraa M. Othman, Eman A. Fayed, Ebtehal M. Husseiny and Hamada S. Abulkhair

Bioorganic Chemistry, 2022, 127, 105968
DOI: 10.1016/j.bioorg.2022.105968

Exploring 1,2,3-triazole-Schiff’s base hybrids as innovative EGFR inhibitors for the treatment of breast cancer: In vitro and in silico study

Nareman A. Nawareg, Asmaa S.A. Yassen, Ebtehal M. Husseiny, Magda A.A. El-Sayed and Hosam A. Elshihawy

Bioorganic Chemistry, 2025, 155, 108106
DOI: 10.1016/j.bioorg.2024.108106

Exploring the cytotoxic effect and CDK-9 inhibition potential of novel sulfaguanidine-based azopyrazolidine-3,5-diones and 3,5-diaminoazopyrazoles

Ebtehal M. Husseiny, Hamada S. Abulkhair, Nehad M. El-Dydamony and Kurls E. Anwer

Bioorganic Chemistry, 2023, 133, 106397
DOI: 10.1016/j.bioorg.2023.106397

Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: Design, synthesis, cytotoxicity evaluation, and mechanistic insights

Yasmin S. Sheta, Marwa T. Sarg, Fatma G. Abdulrahman, Eman S. Nossier and Ebtehal M. Husseiny

Bioorganic Chemistry, 2024, 149, 107471
DOI: 10.1016/j.bioorg.2024.107471

The anticancer and EGFR-TK/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, in vitro , and in silico mechanistic investigations

Arafa Musa, Saleh K. Ihmaid, David L. Hughes, Musa A. Said, Hamada S. Abulkhair, Ahmed H. El-Ghorab, Mohamed A. Abdelgawad, Khaled Shalaby, Mohamed E. Shaker, Khalid Saad Alharbi, Nasser Hadal Alotaibi, Deborah L. Kays, Laurence J. Taylor, Della Grace Thomas Parambi, Sami I. Alzarea, Ahmed A. Al-Karmalawy, Hany E. A. Ahmed and Ahmed M. El-Agrody

Journal of Biomolecular Structure and Dynamics, 2023, 41, 12411
DOI: 10.1080/07391102.2023.2167000

Biological activity of copper porphyrins

Athulya Das, Thasnim P Mohammed and Muniyandi Sankaralingam

Coordination Chemistry Reviews, 2024, 506, 215661
DOI: 10.1016/j.ccr.2024.215661

Recent advances in triazoles as tyrosinase inhibitors

Arif Mermer and Serpil Demirci

European Journal of Medicinal Chemistry, 2023, 259, 115655
DOI: 10.1016/j.ejmech.2023.115655

A bottomless well: 1,2,4-Triazoles continue to inspire scientific researchers to develop more and more anticancer molecules

Hamada S. Abulkhair

Bioorganic & Medicinal Chemistry, 2025, 130, 118389
DOI: 10.1016/j.bmc.2025.118389

The role of the sulfaguanidine molecular scaffold in drug design and development

Hamada S. Abulkhair

Archiv der Pharmazie, 2025, 358
DOI: 10.1002/ardp.202400802

Fluorinated thiazole–thiosemicarbazones hybrids as potential PPAR-γ agonist and α-amylase, α-glucosidase antagonists: Design, synthesis, in silico ADMET and docking studies and hypoglycemic evaluation

Eman A. Fayed, Aya Thabet, Shimaa M. Abd El-Gilil, Heba M.A. Elsanhory and Yousry A. Ammar

Journal of Molecular Structure, 2024, 1301, 137374
DOI: 10.1016/j.molstruc.2023.137374

In vivo evaluation of novel synthetic pyrazolones as CDK9 inhibitors with enhanced pharmacokinetic properties

Ebtehal M Husseiny, Hamada S Abulkhair, Samiha A El-Sebaey, Manal M Sayed and Kurls E Anwer

Future Medicinal Chemistry, 2024, 16, 2487
DOI: 10.1080/17568919.2024.2419363

A decade of research effort in synthesis, biological activity assessments, and mechanistic investigations of sulfamethazine‐incorporating molecules

Hamada S. Abulkhair and Khaled El‐Adl

Archiv der Pharmazie, 2025, 358
DOI: 10.1002/ardp.202500033

Phenylpyrazolone-1,2,3-triazole Hybrids as Potent Antiviral Agents with Promising SARS-CoV-2 Main Protease Inhibition Potential

Arafa Musa, Hamada S. Abulkhair, Ateyatallah Aljuhani, Nadjet Rezki, Mohamed A. Abdelgawad, Khaled Shalaby, Ahmed H. El-Ghorab and Mohamed R. Aouad

Pharmaceuticals, 2023, 16, 463
DOI: 10.3390/ph16030463

Molecular overlay-guided design of new CDK2 inhibitor thiazepinopurines: Synthesis, anticancer, and mechanistic investigations

Ebtehal M. Husseiny, Hamada S. Abulkhair, Asmaa Saleh, Najla Altwaijry, Riham A. Zidan and Fatma G. Abdulrahman

Bioorganic Chemistry, 2023, 140, 106789
DOI: 10.1016/j.bioorg.2023.106789

Design, synthesis, radiolabeling, and mechanistic insights of hydrazinyl imidazolones as broad spectrum antitumor agents with potential carbonic anhydrase inhibition: In vitro, in vivo, and in silico studies

Ebtehal M. Husseiny, Marwa T. Sarg, Yasmin S. Sheta, Manal M. Sayed and Fatma G. Abdulrahman

European Journal of Medicinal Chemistry, 2025, 298, 118049
DOI: 10.1016/j.ejmech.2025.118049

α-Glucosidase-targeting 1,2,4-triazole antidiabetic candidates: comparative analysis and future perspectives

Hamada S. Abulkhair

Future Medicinal Chemistry, 2025, 17, 3025
DOI: 10.1080/17568919.2025.2587561

Bridging the gap with amide linkers: rational design, synthesis, and multi-target evaluation of sulfonamide/acetamide-NSAID hybrids as dual COX-2/5-LOX inhibitors

Triveena M. Ramsis, Shaimaa Hussein, Moustafa S. Abusaif, Ahmed Ragab, Yousry A. Ammar, Omaima Ali, Arafa Musa, Asmaa S. Elzaitony, Mona M. Kamal, Mohammad M. Al-Sanea and Eman A. Fayed

Future Medicinal Chemistry, 2026, 18, 131
DOI: 10.1080/17568919.2025.2605716

In Silico Evaluation of Quinolone–Triazole and Conazole–Triazole Hybrids as Promising Antimicrobial and Anticancer Agents

Humaera Noor Suha, Mansour H. Almatarneh, Raymond A. Poirier and Kabir M. Uddin

IJMS, 2025, 26, 6752
DOI: 10.3390/ijms26146752

Thiocarbohydrazone and Chalcone-Derived 3,4-Dihydropyrimidinethione as Lipid Peroxidation and Soybean Lipoxygenase Inhibitors

Nikitas Georgiou, Eleni Chontzopoulou, Antigoni Cheilari, Aikaterini Katsogiannou, Danai Karta, Kyriaki Vavougyiou, Dimitra Hadjipavlou-Litina, Uroš Javornik, Janez Plavec, Demeter Tzeli, Stamatia Vassiliou and Thomas Mavromoustakos

ACS Omega, 2023, 8, 11966
DOI: 10.1021/acsomega.2c07625

Design, synthesis, characterization and biological evaluation of coumarin bound 1,2,3-triazoles using click chemistry

Jyoti Yadav, C. P. Kaushik, Munish Ahuja, Anil Kumar, Priyanka Yadav and Archna Yadav

Synthetic Communications, 2024, 54, 1808
DOI: 10.1080/00397911.2024.2407435

Comparison between conventional, grinding, and microwave synthesis of methylpyrazoles as VEGFR-2/HSP90 dual inhibitors

Ebtehal M. Husseiny, Rana M. Abdelnaby, Najla Altwaijry, Asmaa Saleh and Kurls E. Anwer

Future Medicinal Chemistry, 2025, 17, 899
DOI: 10.1080/17568919.2025.2485866

Fluorinated indeno-quinoxaline bearing thiazole moieties as hypoglycaemic agents targeting α -amylase, and α -glucosidase: synthesis, molecular docking, and ADMET studies

Nirvana A. Gohar, Eman A. Fayed, Yousry A. Ammar, Ola A. Abu Ali, Ahmed Ragab, Amal M. Mahfoz and Moustafa S. Abusaif

Journal of Enzyme Inhibition and Medicinal Chemistry, 2024, 39
DOI: 10.1080/14756366.2024.2367128

A novel class of phenylpyrazolone-sulphonamides rigid synthetic anticancer molecules selectively inhibit the isoform IX of carbonic anhydrases guided by molecular docking and orbital analyses

Maan T. Khayat, Hany E. A. Ahmed, Abdelsattar M. Omar, Yosra A. Muhammad, Khadijah A. Mohammad, Azizah M. Malebari, Ahdab N. Khayyat, Ahmed H. Halawa, Hamada S. Abulkhair, Ahmed A. Al-Karmalawy, Mohammed Almaghrabi, Majed Alharbi, Anfal S. Aljahdali and Ahmed M. El-Agrody

Journal of Biomolecular Structure and Dynamics, 2023, 41, 15243
DOI: 10.1080/07391102.2023.2188957

Design and Synthesis of Novel Uracil-Linked Schiff Bases As Dual Histone Deacetylase Type II/topoisomerase Type I Inhibitors With Apoptotic Potential

Samar El-Kalyoubi, Samar S Elbaramawi, Ahmed G Eissa, Essam Al-Ageeli, Yahya Hasan Hobani, Aya Ali El-Sharkawy, Hossam Taha Mohamed, Ahmed A Al-Karmalawy and Hamada S Abulkhair

Future Med. Chem., 2023, 15, 937
DOI: 10.4155/fmc-2023-0112

In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies

Sunil Kumar, Iqra Ali, Faheem Abbas, Nimra Khan, Manoj K. Gupta, Manoj Garg, Saroj Kumar and Deepak Kumar

In Silico Pharmacol., 2023, 11
DOI: 10.1007/s40203-023-00157-1

Aminopyridone-Linked Benzimidazoles: A Fragment-Based Drug Design for the Development of CDK9 Inhibitors

Ebtehal M Husseiny, Hamada S Abulkhair, Sanadelaslam SA El-Hddad, Nada Osama and Mona S El-Zoghbi

Future Med. Chem., 2023, 15, 1213
DOI: 10.4155/fmc-2023-0139

The Current Landscape of 1,2,3‐triazole Hybrids With Anticancer Therapeutic Potential: Part II

Zhi Xu and Junna Liu

Archiv der Pharmazie, 2025, 358
DOI: 10.1002/ardp.202500031

Exploring the dual effect of novel 1,4-diarylpyranopyrazoles as antiviral and anti-inflammatory for the management of SARS-CoV-2 and associated inflammatory symptoms

Azizah M. Malebari, Hany E. A. Ahmed, Saleh K. Ihmaid, Abdelsattar M. Omar, Yosra A. Muhammad, Sultan S. Althagfan, Naif Aljuhani, Abdel-Aziz A. A. El-Sayed, Ahmed H. Halawa, Heba M. El-Tahir, Safaa A. Turkistani, Mohammed Almaghrabi, Ahmed K. B. Aljohani, Ahmed M. El-Agrody and Hamada S. Abulkhair

Bioorganic Chemistry, 2023, 130, 106255
DOI: 10.1016/j.bioorg.2022.106255

Design and Synthesis of New Quinazoline Hybrid Molecules as EGFR Targeting Anti‐Breast Cancer Agents

Pandaga Saidulu, Srinivas Bandari, Krishnareddy Valluru and Ravinder Manchal

ChemistrySelect, 2026, 11
DOI: 10.1002/slct.202507086

Pyrano-coumarin hybrids as potential antimicrobial agents against MRSA strains: Design, synthesis, ADMET, molecular docking studies, as DNA gyrase inhibitors

Eman A. Fayed, Maha A. Ebrahim, Usama Fathy, Alaa M. Elawady, Wafaa S. Khalaf and Triveena M. Ramsis

Journal of Molecular Structure, 2024, 1295, 136663
DOI: 10.1016/j.molstruc.2023.136663

Identification of novel thiazolyl-1,2,3-triazole hybrids as potent VEGFR-2 inhibitors for breast cancer treatment

Aya M. Almatary, Mohamed S.H. Salem, Mohamed R. Elnagar, Nahed Nasser Eid El-Sayed, Magda A.-A. El-Sayed, Mohammad M Al-Sanea, Abdelrahman Hamdi, Tarek S. Ibrahim and Mohamed H. Aboutaleb

Journal of Molecular Structure, 2026, 1357, 145203
DOI: 10.1016/j.molstruc.2025.145203

Therapeutic Horizons in Targeting EZH2 With Dual and Non‐PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives

Hamada S. Abulkhair

Archiv der Pharmazie, 2026, 359
DOI: 10.1002/ardp.70212